Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Milestone Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Milestone Pharmaceuticals şirketinin kazançları yıllık ortalama -3.2% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 0.3% oranında azalan oldu. Gelirler yıllık ortalama 13% oranında artan oldu.

Anahtar bilgiler

-3.2%

Kazanç büyüme oranı

40.3%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	6.0%
Gelir büyüme oranı	13.0%
Özkaynak getirisi	-151.4%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

Gelir ve Gider Dağılımı

Milestone Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:MIST Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	0	-48	31	19
31 Mar 24	0	-55	32	24
31 Dec 23	1	-60	31	31
30 Sep 23	5	-59	29	36
30 Jun 23	6	-59	27	39
31 Mar 23	6	-59	26	41
31 Dec 22	5	-58	25	40
30 Sep 22	2	-62	24	68
30 Jun 22	0	-62	22	40
31 Mar 22	15	-44	21	39
31 Dec 21	15	-43	19	39
30 Sep 21	15	-35	16	34
30 Jun 21	15	-32	16	53
31 Mar 21	0	-46	15	31
31 Dec 20	0	-50	16	34
30 Sep 20	0	-60	18	14
30 Jun 20	0	-60	18	24
31 Mar 20	0	-61	18	46
31 Dec 19	0	-55	16	42
30 Sep 19	0	-47	14	35
30 Jun 19	0	-40	12	29
31 Mar 19	0	-29	9	22
31 Dec 18	0	-23	7	17

Kaliteli Kazançlar: MIST şu anda kârlı değil.

Büyüyen Kar Marjı: MIST şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MIST kârlı değildir ve zararlar son 5 yılda yılda 3.2% oranında artmıştır.

Büyüme Hızlandırma: MIST 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: MIST kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 13% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: MIST hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -151.38% ) sahiptir.

Milestone Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

Milestone Pharmaceuticals Appoints Joseph Papa to Its Board of Directors

Milestone Pharmaceuticals Inc., Annual General Meeting, Aug 28, 2024

Milestone Pharmaceuticals Inc. Refreshes Board of Directors

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

New minor risk - Market cap size

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

New minor risk - Profitability

Price target increased by 24% to US$13.00

Forecast to breakeven in 2026

New major risk - Shareholder dilution

Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Price target increased by 21% to US$13.00

Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

Milestone Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS misses analyst expectations

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New minor risk - Shareholder dilution

Milestone Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $29.966667 million.

Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt

Price target decreased by 21% to US$10.75

Forecast to breakeven in 2026

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Price target increased by 13% to US$16.00

Alta Advisers Sends a Letter to Milestone Pharmaceuticals

Insufficient new directors

New minor risk - Market cap size

Milestone Pharmaceuticals Inc. Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

New minor risk - Profitability

Price target increased by 12% to US$16.75

New minor risk - Share price stability

Milestone Pharmaceuticals Inc. Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in the Lancet

Price target decreased by 9.0% to US$14.20

Chief Commercial Officer recently bought US$94k worth of stock

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Milestone Pharmaceuticals Inc. Announces the Retirement of Francis Plat as Chief Scientific Officer, Effective December 31, 2022

Milestone Pharmaceuticals Inc. Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022

Independent Non-Executive Director recently bought US$80k worth of stock

Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

Price target increased to US$15.40

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 Node-302 Study of Etripamil for the Treatment of Psvt

Milestone Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Milestone Pharmaceuticals Appoints David Bharucha as Chief Medical Officer

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Consensus revenue estimates increase to US$15.0m

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

New 90-day low: US$6.52

New 90-day high: US$7.67

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Milestone Pharmaceuticals Inc. Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Milestone Pharmaceuticals Inc. Announces Board Changes

Milestone Pharmaceuticals EPS beats by $0.09

New 90-day low: US$6.00

Milestone Pharmaceuticals Inc. Appoints Lisa Giles and Robert Wills to Board of Directors, Effective October 1, 2020

Milestone Pharmaceuticals Inc. announced that it has received $24.933448 million in funding from RTW Investments, LP

Milestone Pharmaceuticals Inc. announced that it expects to receive $24.933448 million in funding from RTW Investments, LP

New 90-day high - US$8.91

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin